<DOC>
	<DOCNO>NCT00620113</DOCNO>
	<brief_summary>The purpose study ass dose-response percent change baseline lumbar spine bone mineral density ( BMD ) lumbar vertebra 1 4 ( L1- L4 ) odanacatib ( MK-0822 ) 10 mg , 25 mg , 50 mg placebo orally administer weekly 52 week Japanese involutional osteoporosis participant . The study also assess safety tolerability odanacatib ( 10 , 25 , 50 mg ) participant . The study enroll approximately 280 participant randomly assign 3 different dos odanacatib placebo 52 week , along supplemental vitamin D3 calcium carbonate . The primary efficacy hypothesis dose-response relationship percent change baseline lumbar spine BMD ( L1- L4 ) see odanacatib 10 , 25 , 50 mg placebo orally administer weekly 52 week involutional osteoporosis participant . The primary safety hypothesis odanacatib safe well tolerate 52 week involutional osteoporosis participant .</brief_summary>
	<brief_title>Efficacy Safety Odanacatib ( MK-0822 ) Participants With Involutional Osteoporosis ( MK-0822-022 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Postmenopausal woman ( least 5 year ) men age 45 85 Participant low bone mineral density Participant anatomy suitable dualenergy xray absorptiometry ( DXA ) lumber spine hip Participant ambulatory ( walk ) Participant secondary osteoporosis metabolic bone disorder osteoporosis osteopenia Participant receive osteoporosis medication medication affect bone Participant already participate another drug study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>